Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Large intragenic deletion of CDC73 (exons 4-10) in a three-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family.
|
28774260 |
2017 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Pathogenic germline CDC73 variants were identified in 11 of the 89 referred pHPT patients (12.4%), with (suspected) hyperparathyroidism-jaw tumor (HPT-JT) syndrome (n = 3), familial isolated pHPT (n = 5), apparently sporadic parathyroid carcinoma (n = 2), and apparently sporadic parathyroid adenoma (n = 1).
|
29040582 |
2017 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Moreover, CDC73 germline mutations occur in 20%-40% of patients with sporadic PC and may reveal unrecognized HPT-JT.
|
28881068 |
2017 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Most pathogenic CDC73 missense mutations associated with the HPT-JT syndrome are located in the region encoding CDC73-NTD.
|
29142233 |
2017 |
Parathyroid Gland Adenocarcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Loss of parafibromin immunostaining has been shown in most PC.
|
27001435 |
2016 |
Parathyroid Gland Adenocarcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This is the first case documenting a germline 70 G>T HRPT2/CDC73 gene mutation in a pediatric parathyroid carcinoma.
|
27544721 |
2016 |
Parathyroid Gland Adenocarcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
A case of pediatric parathyroid carcinoma associated with haploinsufficiency of CDC73 is discussed.
|
26650250 |
2016 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
Biomarker
|
disease |
BEFREE |
Parafibromin is a protein encoded by hyperparathyroidism 2 (HRPT2) and its downregulated expression is involved in the pathogenesis of parathyroid, breast, gastric, colorectal, lung, head and neck cancers.
|
26409451 |
2016 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
It also highlights the fact that HPT-JT should be considered and CDC73 mutation analysis should be performed in cases of early-onset PHPT associated with ossifying fibromas of the jaw.
|
26995009 |
2016 |
Parathyroid Gland Adenocarcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The importance of CDC73 in PC is reinforced with a remarkable preferential amplification of the mutant CDC73 allele.
|
25387265 |
2015 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The present case highlights that HPT-JT should be considered and CDC73 mutation analysis should be performed, especially in cases of early-onset PHPT, recurrent PHPT, PHPT with polyglandular parathyroid involvement, and PHPT presenting with severe hypercalcemia even if there is no positive family history.
|
25959515 |
2015 |
Parathyroid Gland Adenocarcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A previously unreported intragenic deletion of exons 1 to 10 of CDC73 was detected in a three-generation family with FIHP, due to adenomas, atypical adenomas, and parathyroid carcinomas.
|
24823466 |
2014 |
Parathyroid Gland Adenocarcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our gene expression profiling experiments suggest that upregulated FGFR1 expression appears to be associated with parathyroid carcinoma in HPT-JT syndrome due to an HRPT2 splicing mutation.
|
24889687 |
2014 |
Parathyroid Gland Adenocarcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The CDC73 gene, encoding parafibromin, has been identified as a tumour suppressor gene both in hyperparathyroidism-jaw tumour (HPT-JT) syndrome and in sporadic parathyroid carcinoma.
|
25113791 |
2014 |
Parathyroid Gland Adenocarcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
However, proponents have found immunohistochemistry for parafibromin useful to definitively confirm a pathological diagnosis of parathyroid carcinoma, predict a worse outcome in definite parathyroid carcinomas, triage formal genetic testing for HPT-JT syndrome, and predict the outcome of histologically atypical parathyroid adenomas.
|
24402736 |
2014 |
Parathyroid Gland Adenocarcinoma
|
0.800 |
CausalMutation
|
disease |
CLINVAR |
Hyperparathyroidism-jaw tumor syndrome: Results of operative management.
|
25444225 |
2014 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Hyperparathyroidism-jaw tumor syndrome (HPT-JT) is a rare, autosomal-dominant disease secondary to germline-inactivating mutations of the tumor suppressor gene HRPT2/CDC73.
|
25444225 |
2014 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CDC73 mutations frequently underlie the hyperparathyroidism-jaw tumor syndrome, familial isolated hyperparathyroidism (FIHP), and parathyroid carcinoma.
|
24823466 |
2014 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We report a novel mutation in the CDC73 gene that may underlie HPT-JT syndrome.
|
25113791 |
2014 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
Biomarker
|
disease |
BEFREE |
Whether FIHP is a variant or an early stage of MEN1 syndrome or hyperparathyroidism-jaw tumor syndrome is yet to be established.
|
24121387 |
2014 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our gene expression profiling experiments suggest that upregulated FGFR1 expression appears to be associated with parathyroid carcinoma in HPT-JT syndrome due to an HRPT2 splicing mutation.
|
24889687 |
2014 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
To present the case of a hyperparathyroidism-jaw tumor (HPT-JT) patient with a novel nonsense mutation of the CDC73 gene.
|
23757631 |
2014 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.800 |
Biomarker
|
disease |
BEFREE |
However, proponents have found immunohistochemistry for parafibromin useful to definitively confirm a pathological diagnosis of parathyroid carcinoma, predict a worse outcome in definite parathyroid carcinomas, triage formal genetic testing for HPT-JT syndrome, and predict the outcome of histologically atypical parathyroid adenomas.
|
24402736 |
2014 |
Parathyroid Gland Adenocarcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Previous studies, mostly based on familial cases of the disease, suggested potential roles for the tumour suppressor MEN1 and proto-oncogene RET in benign parathyroid tumourigenesis, while the tumour suppressor HRPT2 and proto-oncogene CCND1 may also act as drivers in parathyroid cancer.
|
23616356 |
2013 |
Parathyroid Gland Adenocarcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In HPT-JT, mutations of CDC73/HRPT2 are associated with parathyroid carcinoma, but tumors of the kidneys and uterus are additional features.
|
23652676 |
2013 |